Body mass index
Item
body mass index (bmi) ≥ 27 and ≤ 40 kg/m2
boolean
C1305855 (UMLS CUI [1])
Homeostasis model assessment Insulin Resistance
Item
homa-ir ≥ 2.5
boolean
C1829779 (UMLS CUI [1,1])
C0021655 (UMLS CUI [1,2])
Non-smoker
Item
non-smoking
boolean
C0337672 (UMLS CUI [1])
Serum total cholesterol measurement | Serum LDL cholesterol measurement | Gender | Age
Item
total cholesterol and ldl cholesterol <95th percentile for sex and age
boolean
C1445957 (UMLS CUI [1])
C0428474 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
C0001779 (UMLS CUI [4])
Serum fasting triglyceride measurement
Item
fasting triglycerides < 500mg/dl
boolean
C0582824 (UMLS CUI [1])
Fasting Blood Sugar Measurement
Item
fasting blood sugar < 126
boolean
C2825162 (UMLS CUI [1])
Urinary Microalbumin Assay
Item
urinary microalbumin < 30 mg/l
boolean
C2981750 (UMLS CUI [1])
Serum TSH level normal
Item
normal thyroid stimulating hormone levels
boolean
C0580433 (UMLS CUI [1])
Hematocrit procedure
Item
hematocrit ≥ 36%
boolean
C0018935 (UMLS CUI [1])
Blood pressure measurement
Item
blood pressure < 150/90
boolean
C0005824 (UMLS CUI [1])
Stable body weight | Requirement Body Weight Maintenance | Diet
Item
at least 3 months of a weight-stable state (± 5 lbs) prior to the study. during the study, subjects will be required to maintain their body weight within ± 3% (up to a maximum change of 5 lbs) of their initial weight over the course of any consecutive two weeks after the second week of baseline diet or during the last week of each diet phase
boolean
C0517386 (UMLS CUI [1])
C1514873 (UMLS CUI [2,1])
C4042910 (UMLS CUI [2,2])
C0012155 (UMLS CUI [3])
Coronary heart disease | Cerebrovascular Disorder | Peripheral Vascular Disease | Blood Coagulation Disorders | Liver disease | Kidney Disease | Diabetes Mellitus | Lung disease | HIV Infection | Malignant Neoplasms | Exception Skin carcinoma
Item
history of coronary heart disease, cerebrovascular disease, peripheral vascular disease, bleeding disorder, liver or renal disease, diabetes, lung disease, hiv, or cancer (other than skin cancer) in the last 5 years
boolean
C0010068 (UMLS CUI [1])
C0007820 (UMLS CUI [2])
C0085096 (UMLS CUI [3])
C0005779 (UMLS CUI [4])
C0023895 (UMLS CUI [5])
C0022658 (UMLS CUI [6])
C0011849 (UMLS CUI [7])
C0024115 (UMLS CUI [8])
C0019693 (UMLS CUI [9])
C0006826 (UMLS CUI [10])
C1705847 (UMLS CUI [11,1])
C0699893 (UMLS CUI [11,2])
Pharmaceutical Preparations Affecting Lipid Metabolism | Pharmaceutical Preparations Affecting Insulin Resistance | Hormone preparation | Anticoagulants | Warfarin
Item
use of drugs known to affect lipid metabolism or insulin resistance, hormones, or the blood thinning agent, warfarin
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0598783 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0021655 (UMLS CUI [2,3])
C0019932 (UMLS CUI [3])
C0003280 (UMLS CUI [4])
C0043031 (UMLS CUI [5])
Alcohol consumption | Dietary Supplements
Item
use of alcohol or dietary supplements during the study
boolean
C0001948 (UMLS CUI [1])
C0242295 (UMLS CUI [2])
Pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])